AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21129944 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 μg/nasal cavity twice daily
Number of subjects: 63
Study 21129944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 19001519 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized GH dose (17-100 microg/kg.d)
Number of subjects: 153
Study 19001519 — intervention group
Group type: COMPARATOR
Intervention: Standard GH dose (43 microg/kg.d)
Number of subjects: 153
Study 19001519 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GH-deficient and ISS groups
Number of subjects: 153
Study 16730488 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib, 40 mg, once a day for 5 days
Number of subjects: 51
Study 16730488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 15380400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 318
Study 15380400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 10904459 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 5 mg/d
Number of subjects: 23
Study 10904459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9265698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pair-matched design
Number of subjects: 0
Study 9265698 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified designs
Number of subjects: 0
Study 8319521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified diet education
Number of subjects: 86
Study 8319521 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 86
Study 3521187 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 128
Study 3521187 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 128
Study 3521187 — intervention group
Group type: COMPARATOR
Intervention: Single-drug chemotherapy
Number of subjects: 128
Study 28281940 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination
Number of subjects: 203
Study 28281940 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial identity
Number of subjects: 203
Study 28281940 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderation of discrimination by racial identity
Number of subjects: 203
Study 27400960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy intervention (2 times per week for 9 weeks) including specific exercises, motor control exercises, or traction, along with a tailor-made supervised exercise program.
Number of subjects: 202
Study 27400960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy intervention
Number of subjects: 202
Study 27400960 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (control) receiving standardized information about surgery, post-surgical rehabilitation, and advice to stay active.
Number of subjects: 202
Study 23722575 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat reposition with pedicled infraorbital fat redraping (Group 1)
Number of subjects: 120
Study 23722575 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal reset to reposition the underlying fat (Group 2)
Number of subjects: 120
Study 23722575 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal reset (Group 2)
Number of subjects: 120
Study 22829267 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC (4 × 10(7) /injection) via intra-arterial and intravenous routes
Number of subjects: 33
Study 22829267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 20370417 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sodium phosphosilicate dentifrice
Number of subjects: 110
Study 20370417 — intervention group
Group type: COMPARATOR
Intervention: Potassium nitrate dentifrice
Number of subjects: 110
Study 20370417 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 110
Study 18206738 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillator therapy
Number of subjects: 786
Study 18206738 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 786
Study 18206738 — intervention group
Group type: COMPARATOR
Intervention: No ICD therapy (control group)
Number of subjects: 786
Study 15999885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel (15 mL of 2% lidocaine administered intrarectally ten minutes before biopsy)
Number of subjects: 356
Study 15999885 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine periprostatic infiltration (10 mL of 1% lidocaine given under ultrasound guidance in two periprostatic injections of 5 mL, four minutes before biopsy)
Number of subjects: 356
Study 12450598 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (half-dose reteplase and full-dose abciximab)
Number of subjects: 553
Study 12450598 — intervention group
Group type: COMPARATOR
Intervention: Reteplase (standard-dose)
Number of subjects: 553
Study 10363737 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 0.5% ophthalmic solution
Number of subjects: 176
Study 10363737 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 176
Study 7574130 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine
Number of subjects: 154
Study 7574130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol
Number of subjects: 154
Study 7574130 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine and nebulized metaproterenol
Number of subjects: 154
Study 2183055 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of continuous intravenous heparin with warfarin sodium begun on the first day
Number of subjects: 199
Study 2183055 — intervention group
Group type: COMPARATOR
Intervention: 10-day course of intravenous heparin with warfarin sodium begun on the fifth day
Number of subjects: 199
Study 2183055 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of continuous intravenous heparin
Number of subjects: 199
Study 2183055 — intervention group
Group type: COMPARATOR
Intervention: 10-day course of intravenous heparin
Number of subjects: 199
Study 6104634 — intervention group
Group type: EXPERIMENTAL
Intervention: GYKI-41099 2.5, 5 and 10 mg
Number of subjects: 18
Study 6104634 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 10, 20 and 40 mg
Number of subjects: 18
Study 6104634 — intervention group
Group type: EXPERIMENTAL
Intervention: GYKI-41099 5-15 mg daily for 2 months
Number of subjects: 18
Study 6104634 — intervention group
Group type: EXPERIMENTAL
Intervention: GYKI-41099 in patients with mild hypertension
Number of subjects: 18
Study 31851666 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Medical Group Visits (IMGV)
Number of subjects: 159
Study 31851666 — intervention group
Group type: COMPARATOR
Intervention: Primary Care Provider (PCP) visit
Number of subjects: 159
Study 30099412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger supplementation (2g ginger powder for 10 weeks)
Number of subjects: 45
Study 30099412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2g wheat flour for 10 weeks)
Number of subjects: 45
Study 26786921 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 825
Study 25155980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held device with evidence-based software
Number of subjects: 0
Study 25155980 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22040870 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diet
Number of subjects: 466
Study 22040870 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 466
Study 22040870 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual dietary PUFA:SFA ratio×PPARG Pro12Ala genotype interaction
Number of subjects: 466
Study 22040870 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARA Val162Leu×PPARG Pro12Ala genotype interaction
Number of subjects: 466
Study 19169239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 0.04 ml/1 mg
Number of subjects: 28
Study 19169239 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy plus intravitreal triamcinolone (PDT+IVTA) 0.1 ml/4 mg
Number of subjects: 28
Study 17378845 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 788
Study 17378845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 788
Study 15529514 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide combination tablets (Glucovance)
Number of subjects: 477
Study 11345366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (BK) administered at graded doses (0.2, 0.6, 2.0 microg/min) in ACE inhibitor group
Number of subjects: 56
Study 11345366 — intervention group
Group type: COMPARATOR
Intervention: Bradykinin (BK) administered at graded doses (0.2, 0.6, 2.0 microg/min) in non-ACE inhibitor group
Number of subjects: 56
Study 11345366 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine (ACh) (30 microg/min)
Number of subjects: 56
Study 11345366 — intervention group
Group type: COMPARATOR
Intervention: Papaverine (PA) (12 mg)
Number of subjects: 56
Study 8989000 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-dose hypobaric solution of 1% lidocaine 25 mg with fentanyl 25 micrograms
Number of subjects: 30
Study 8989000 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose hyperbaric solution of 5% lidocaine 75 mg
Number of subjects: 30
Study 8085040 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive motion rehabilitation with an automatic device (Toronto Mobilimb) for 2 hours per day
Number of subjects: 120
Study 8085040 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation program
Number of subjects: 120
Study 8085040 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive motion rehabilitation with an automatic device (Toronto Mobilimb)
Number of subjects: 120
Study 3315687 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline preparation (18 mg/kg per day at 2000 hours)
Number of subjects: 20
Study 3315687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31758401 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 0
Study 31758401 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31197364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish containing 1.5% ammonium fluoride applied every sixth week during orthodontic treatment.
Number of subjects: 182
Study 31197364 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish without fluoride applied every sixth week during orthodontic treatment.
Number of subjects: 182
Study 31197364 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (Control)
Number of subjects: 182
Study 28463940 — intervention group
Group type: EXPERIMENTAL
Intervention: SGS 2.5%
Number of subjects: 76
Study 28463940 — intervention group
Group type: COMPARATOR
Intervention: NS
Number of subjects: 76
Study 26828596 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic stone extraction (ERCP) followed by laparoscopic cholecystectomy (LC) and intraoperative cholangiogram (IOC)
Number of subjects: 0
Study 26828596 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 24166941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 40
Study 24166941 — intervention group
Group type: COMPARATOR
Intervention: Non‐specific neurocognitive therapy (NNT)
Number of subjects: 40
Study 23163144 — intervention group
Group type: EXPERIMENTAL
Intervention: Restitution combined with percutaneous vertebroplasty (PVP)
Number of subjects: 132
Study 23163144 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 132
Study 23163144 — intervention group
Group type: EXPERIMENTAL
Intervention: Restitution combined with PVP
Number of subjects: 132
Study 19827964 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical morphine solution (2 per thousand)
Number of subjects: 9
Study 19827964 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 9
Study 17440161 — intervention group
Group type: EXPERIMENTAL
Intervention: PELFw regimen (8 weekly administrations of cisplatin 40 mg/m2, LV 250 mg/m2, epidoxorubicin 35 mg/m2, 5-FU 500 mg/m2, glutathione 1.5 g/m2 with filgrastim)
Number of subjects: 400
Study 17440161 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV regimen (6 monthly administrations of a 5-day course of 5-FU 375 mg/m2 daily and LV 20 mg/m2 daily)
Number of subjects: 400
Study 16125523 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine supplementation
Number of subjects: 70
Study 16125523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 70
Study 16125523 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modifications and increased physical activity
Number of subjects: 70
Study 12123399 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/d ER niacin
Number of subjects: 148
Study 12123399 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/d ER niacin
Number of subjects: 148
Study 10354968 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (800 mg every 8 hours from days 2 to 7)
Number of subjects: 16
Study 10354968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9420871 — intervention group
Group type: COMPARATOR
Intervention: Micronized estradiol (n = 8)
Number of subjects: 23
Study 9420871 — intervention group
Group type: COMPARATOR
Intervention: Micronized progesterone (n = 8)
Number of subjects: 23
Study 9420871 — intervention group
Group type: COMPARATOR
Intervention: Combination of micronized estradiol and progesterone (n = 7)
Number of subjects: 23
Study 2048454 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand-switching procedure
Number of subjects: 110
Study 2048454 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-stage set of 'Nicotine Faders' graduated filters
Number of subjects: 110
Study 2048454 — intervention group
Group type: COMPARATOR
Intervention: Both methods (Brand-switching and Nicotine Faders)
Number of subjects: 110
Study 7316248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush Immunotherapy (IT) with four Ag dilutions: 10, 100, 1000, and 5000 pnu/ml, maintenance dose of 0.5 ml of the 5000 pnu/ml solution achieved in 7 to 18 weeks (mean 12 weeks).
Number of subjects: 13
Study 7316248 — intervention group
Group type: COMPARATOR
Intervention: Control group: Five patients who had repeat BPTs to the same Ag without IT.
Number of subjects: 13
Study 30993855 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 units/mL (Gla-300)
Number of subjects: 638
Study 30993855 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL (Gla-100)
Number of subjects: 638
Study 28256054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (LIXI)
Number of subjects: 1198
Study 28256054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1198
Study 25683938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib combined with RFA (n=30)
Number of subjects: 62
Study 25683938 — intervention group
Group type: COMPARATOR
Intervention: RFA alone (n=32)
Number of subjects: 62
Study 24644241 — intervention group
Group type: EXPERIMENTAL
Intervention: high-fat/exercise
Number of subjects: 6
Study 24644241 — intervention group
Group type: COMPARATOR
Intervention: high-fat/sedentary
Number of subjects: 6
Study 24644241 — intervention group
Group type: EXPERIMENTAL
Intervention: low-fat/exercise
Number of subjects: 6
Study 24644241 — intervention group
Group type: COMPARATOR
Intervention: low-fat/sedentary
Number of subjects: 6
Study 22644173 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Number of subjects: 18
Study 22644173 — intervention group
Group type: COMPARATOR
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 18
Study 20012810 — intervention group
Group type: EXPERIMENTAL
Intervention: TAAG intervention
Number of subjects: 0
Study 17317857 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (140 mg)
Number of subjects: 150
Study 17317857 — intervention group
Group type: COMPARATOR
Intervention: High-dose imatinib (800 mg)
Number of subjects: 150
Study 15345173 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (He-Ne laser applied to three trigger points in the upper trapezius muscles with 632.8 nm)
Number of subjects: 60
Study 15345173 — intervention group
Group type: COMPARATOR
Intervention: Dry needling
Number of subjects: 60
Study 15345173 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 60
Study 11274941 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TLR)
Number of subjects: 188
Study 11274941 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study 9893457 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week prednisolone + 2-year Sairei-to
Number of subjects: 196
Study 9893457 — intervention group
Group type: COMPARATOR
Intervention: 18-week prednisolone + 2-year Sairei-to
Number of subjects: 196
Study 8276650 — intervention group
Group type: EXPERIMENTAL
Intervention: Early locoregional radiotherapy (40 Gy in 15 fractions in 3 weeks)
Number of subjects: 308
Study 8276650 — intervention group
Group type: COMPARATOR
Intervention: Late locoregional radiotherapy (40 Gy in 15 fractions in 3 weeks)
Number of subjects: 308
Study 3885672 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 68
Study 3885672 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 50 mg
Number of subjects: 68
Study 3885672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 31186177 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Bone Scan Index (aBSI) increase during treatment
Number of subjects: 176
Study 31186177 — intervention group
Group type: COMPARATOR
Intervention: Control group (aBSI change >0.3)
Number of subjects: 176
Study 29913318 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Wellbeing interventions
Number of subjects: 0
Study 27564283 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin Oral Intake Therapy (4 mg once daily for 4 weeks)
Number of subjects: 239
Study 27564283 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin Oral Intake Therapy
Number of subjects: 239
Study 27564283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 24169147 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg PO twice daily for six weeks
Number of subjects: 60
Study 24169147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24169147 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 60
Study 22429179 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based cases
Number of subjects: 5224
Study 22429179 — intervention group
Group type: COMPARATOR
Intervention: Text-based cases
Number of subjects: 5224
Study 20407232 — intervention group
Group type: EXPERIMENTAL
Intervention: Late GH therapy (0.46 mg/kg/week)
Number of subjects: 58
Study 20407232 — intervention group
Group type: EXPERIMENTAL
Intervention: Early GH therapy (0.46 mg/kg/week)
Number of subjects: 58
Study 20407232 — intervention group
Group type: COMPARATOR
Intervention: No GH therapy (Control)
Number of subjects: 58
Study 18039957 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intensity postinduction intensification (PII)
Number of subjects: 2078
Study 18039957 — intervention group
Group type: COMPARATOR
Intervention: Standard duration postinduction intensification (PII)
Number of subjects: 2078
Study 18039957 — intervention group
Group type: COMPARATOR
Intervention: Longer duration postinduction intensification (PII)
Number of subjects: 2078
Study 17886000 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 17886000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15159317 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction group (smokers reducing CPD by 25% to 75%)
Number of subjects: 151
Study 15159317 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (baseline measurements before joining reduction group)
Number of subjects: 151
Study 11432176 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive multimodal analgesia (diclofenac, butorphanol, and lidocaine)
Number of subjects: 82
Study 11432176 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preemptive multimodal analgesia)
Number of subjects: 82
Study 9183129 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) titrated to a target dose of 0.7 mg/kg twice a day
Number of subjects: 91
Study 9183129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 1537636 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy intervention
Number of subjects: 0
Study 3895761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 200 mg/day
Number of subjects: 12
Study 3895761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 400 mg/day
Number of subjects: 12
Study 3895761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 600 mg/day
Number of subjects: 12
Study 3895761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30679315 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle with erlotinib 100 mg p.o. daily (Arm A)
Number of subjects: 92
Study 30679315 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle with erlotinib 100 mg p.o. daily and panitumumab 4 mg/kg on days 1 and 15 of a 28-day cycle (Arm B)
Number of subjects: 92
Study 28635375 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy
Number of subjects: 0
Study 26763949 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-week (3 times/wk) progressive mixed (aerobic/strength/balance/flexibility) community group exercise program
Number of subjects: 40
Study 26763949 — intervention group
Group type: COMPARATOR
Intervention: Matched duration home stretching program
Number of subjects: 40